Alzheimer’s Registry Launch, Analyst Price Targets, and 2026 Catalysts (Dec. 18, 2025)
WALTHAM, Mass. / Markets — December 18, 2025: Thermo Fisher Scientific Inc. (NYSE: TMO) is in focus Thursday as investors weigh a new Alzheimer’s real‑world evidence initiative from its PPD CorEvitas clinical registries business alongside a steady stream of Wall Street forecasts and valuation takes. Shares were trading around $561 in the afternoon, modestly lower on the day, after a 1.33% decline in Wednesday’s session. [1]
Below is a complete, publication-ready roundup of the news, forecasts, and market analysis circulating on December 18, 2025—plus what it could mean for Thermo Fisher stock as 2026 approaches.
TMO stock price check: where Thermo Fisher shares trade on Dec. 18, 2025
Thermo Fisher stock hovered near $561 on…
